reports
Sanofi: 1 director
A director at Sanofi bought 500 shares at 82.700EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
- Bruno Cavalier
- Jerôme Bodin
- Bruno Cavalier
- Jerôme Bodin
Press release: Availability of the Q2 2025 Aide mémoire
Press release: Availability of the Q2 2025 Aide mémoire Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second quarter 2025 results will be published on July 31, 2025. About Sanofi...
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire...
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire » Mise en ligne du document «Q2 2025 Aide mémoire » Paris, France, le 30 juin 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q2 2025 Aide mémoire ». Comme chaque trimestre, ce document vise à assister la communauté financière dans la modélisation des résultats trimestriels de la société. Ce document contient un rappel de divers éléments non récurrents, l’effet des variations monétaires et le nombre d’actions. Les résultats du premier tri...
Press Release: Riliprubart granted orphan drug designation in Japan fo...
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatmentJapanese Ministry of Health, Labour and Welfare decision adds to similar designations in the US and Europe, underscoring global regulatory recognition of the potential for riliprupart to address significant unmet medical needs for people living...
Communiqué de presse : Le riliprubart obtient la désignation de médica...
Communiqué de presse : Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Deux études de phase 3 sont actuellement en cours pour tester le riliprubart chez les personnes atteintes de PIDC comme traitement potentiel meilleur de sa catégorieLa décision du ministère de la Santé, du Travail et des Affaires sociales du Japon s’ajoute aux désignations similaires aux États-Unis et en ...
- Carole Braudeau
- Carole Braudeau
- Olfa Taamallah
- Yan Derocles
MTX MTU AERO ENGINES AG
HO THALES SA
FGA FIGEAC AERO SA
RHM RHEINMETALL AG
BRBY BURBERRY GROUP PLC
FII LISI SA
GOE GROUPE GORGE SA
SAF SAFRAN S.A.
AIR AIRBUS SE
BA. BAE SYSTEMS PLC
AIXA AIXTRON SE
VASTB VASTNED RETAIL BELGIUM NV
ARG ARGAN SA
FACC FACC AG
LDO LEONARDO SPA
DUFN DUFRY AG
HAG HENSOLDT AG
AERO MONTANA AEROSPACE AG
AM DASSAULT AVIATION
LAT LATECOERE
R3NK RENK GROUP AG
EXENS EXOSENS
CAN CANAL+
- Olfa Taamallah
- Yan Derocles
ENGI ENGIE SA.
BNP BNP PARIBAS SA CLASS A
MTX MTU AERO ENGINES AG
HO THALES SA
FGA FIGEAC AERO SA
MUV2 MUNICH REINSURANCE COMPANY
RHM RHEINMETALL AG
EL ESSILORLUXOTTICA SA
FII LISI SA
GOE GROUPE GORGE SA
G ASSICURAZIONI GENERALI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
SAF SAFRAN S.A.
AIR AIRBUS SE
01913 PRADA S.P.A.
BA. BAE SYSTEMS PLC
AMS AMADEUS IT GROUP SA CLASS A
FACC FACC AG
LDO LEONARDO SPA
SIE SIEMENS AG
HAG HENSOLDT AG
AERO MONTANA AEROSPACE AG
AM DASSAULT AVIATION
LAT LATECOERE
R3NK RENK GROUP AG
EXENS EXOSENS
- Olfa Taamallah
- Yan Derocles
MTX MTU AERO ENGINES AG
HO THALES SA
FGA FIGEAC AERO SA
RHM RHEINMETALL AG
BRBY BURBERRY GROUP PLC
FII LISI SA
GOE GROUPE GORGE SA
SAF SAFRAN S.A.
AIR AIRBUS SE
BA. BAE SYSTEMS PLC
AIXA AIXTRON SE
VASTB VASTNED RETAIL BELGIUM NV
ARG ARGAN SA
FACC FACC AG
LDO LEONARDO SPA
DUFN DUFRY AG
HAG HENSOLDT AG
AERO MONTANA AEROSPACE AG
AM DASSAULT AVIATION
LAT LATECOERE
R3NK RENK GROUP AG
EXENS EXOSENS
CAN CANAL+
- Olfa Taamallah
- Yan Derocles
ENGI ENGIE SA.
BNP BNP PARIBAS SA CLASS A
MTX MTU AERO ENGINES AG
HO THALES SA
FGA FIGEAC AERO SA
MUV2 MUNICH REINSURANCE COMPANY
RHM RHEINMETALL AG
EL ESSILORLUXOTTICA SA
FII LISI SA
GOE GROUPE GORGE SA
G ASSICURAZIONI GENERALI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
SAF SAFRAN S.A.
AIR AIRBUS SE
01913 PRADA S.P.A.
BA. BAE SYSTEMS PLC
AMS AMADEUS IT GROUP SA CLASS A
FACC FACC AG
LDO LEONARDO SPA
SIE SIEMENS AG
HAG HENSOLDT AG
AERO MONTANA AEROSPACE AG
AM DASSAULT AVIATION
LAT LATECOERE
R3NK RENK GROUP AG
EXENS EXOSENS
- Louis Boujard
- CFA
- Philippe Ourpatian
- Fehmi Ben Naamane
- Benoit Valleaux
- Roland Pfaender
- MBA
- CFA
- CCRA
- Fehmi Ben Naamane
- Louis Boujard
- CFA
- Philippe Ourpatian
- Carole Braudeau
- Carole Braudeau
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.